A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
NCT ID: NCT01860508
Last Updated: 2013-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
94 participants
INTERVENTIONAL
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC
NCT03700333
A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients
NCT05210946
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
NCT01769066
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
NCT01531790
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
NCT05055908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pemetrexed
pemetrexed /carboplatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pemetrexed /carboplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer
* Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD
* Presence of at least one index lesion measurable by CT scan or MRI
* leucocyte ≥ 3.5×109/L
* neutrophil ≥ 1.5×109/L
* platelet ≥ 80×109/L
* Hemoglobin ≥ 9g/L
* ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN
* BUN≤ 1.5×ULN
* Signed written informed consent
Exclusion Criteria
* Patients were allergic to pemetrexed
* Patients received chemotherapy before
* Uncontrolled acute infection
.Uncontrolled pleural effusion
* Severe symptomatic heart disease
* Severe infection or metabolic disfunction
* Patients with other malignant tumor
* Uncontrolled brain metastases
* Patients have accepted other clinical trials
* Female patients during their pregnant and lactation period, or patients without contraception
* Mental disorientation of disorder
* Glucocorticoids taboo
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jialei Wang
Attending doctor of medical oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer hospital Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhao X, Yu H, Zhao J, Wu X, Sun S, Luo Z, Wang H, Qiao J, Chang J, Wang J. Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer. Oncotarget. 2017 Sep 23;8(49):86384-86394. doi: 10.18632/oncotarget.21186. eCollection 2017 Oct 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-PEM-WJL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.